Harvard Bioscience Third-Quarter Revenue Grows 8 Percent to $22.2 Million, With a $2.6 Million Net Loss, and Full-Year Guidance Reaffirmed
Harvard Bioscience announced financial results for the third quarter ended September 30, 2026, in Holliston, Massachusetts, on November 10, 2026. Third-quarter revenue was $22.2 million, compared with $20.6 million a year earlier, an increase of 8 percent.
Gross profit was $12.3 million, compared with $12.0 million a year earlier, and gross margin was 55.4 percent, compared with 58.4 percent. Adjusted gross profit was $12.7 million and adjusted gross margin was 57.1 percent.
The net loss for the quarter was $2.6 million, compared with a net loss of $1.2 million a year earlier. Revenue for the first nine months of 2026 was $65.7 million, compared with $62.8 million a year earlier.
President and Chief Executive Officer John Duke said the quarter was the second consecutive quarter of strong year-over-year growth. The company reaffirmed full-year 2026 revenue guidance of 3 percent to 5 percent year-over-year growth.
(Source: Harvard Bioscience)
Source: Harvard Bioscience
Published by GSM · USA (original Chinese edition)
Photo: 图：实验室研究人员工作中（资料图）。照片：CC0，经 Wikimedia Commons。 / Photo: Researchers at work in a laboratory (file photo). CC0, via Wikimedia Commons.
